AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca leaned on cancer drugs in the third-quarter, leading to double-digit sales growth, a strong beat and a jump for AZN stock. The post AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth appeared first on Investor's Business Daily.

AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth

AstraZeneca PLC (NASDAQ:AZN) stock is up 7% at $65.30 at last glance, after the biotech name posted an upbeat third-quarter report and raised forecast.

AstraZeneca Stock Surges on Upbeat Earnings, Forecast

Today, TIME named AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab) on their 2022 list of Best Inventions. Their selection of EVUSHELD reflects its impact as the first and only long-acting monoclonal antibody to receive emergency use authorization in the US for the prevention of COVID-19 in immunocompromised people.

AstraZeneca EVUSHELD Named on TIME's List of the Best Inventions of 2022

Coca-Cola

These stocks both pay more than 2% per year in dividends.

Worried About a Recession? Park Your Money In These 2 High-Yielding Dividend Stocks

Drug giant says it will no longer seek U.S. approval for the shot, citing a likely lack of demand.

AstraZeneca Drops Plan to Sell Covid-19 Vaccine in U.S.

AstraZeneca is no longer pursuing U.S. approval of its COVID-19 vaccine, Chief Executive Pascal Soriot said in a media call on Thursday.

(OFFICIAL) AstraZeneca no longer pursuing U.S. approval for COVID vaccine

AstraZeneca PLC (LSE:AZN) has increased its earnings guidance after a strong quarter during which EPS grew by 70% at constant exchange rates. The Anglo-Swedish drugs giant says it now expects 2022 core EPS to increase by the high-twenties to low-thirties percent.

AstraZeneca raises earnings guidance as profit margins improve

AstraZeneca lifts guidance after forecast-beating profit sales

AstraZeneca on Thursday topped analysts' expectations for third-quarter profit and revenue, helped by sales of its key cancer drugs, and raised its full-year adjusted earnings forecast.

AstraZeneca tops quarterly estimates buoyed by cancer drug sales

AZN shares have been a bright spot in an otherwise dim market in 2022, up nearly 8% and widely outperforming the general market.

AstraZeneca Q3 Preview: Can Shares Stay Strong?

On CNBC's "Options Action," Michael Khouw of Optimize Advisors said that AstraZeneca plc. (NASDAQ: AZN) traded 3.9 times its average daily put volume on Tuesday.

Options Traders Expect AstraZeneca Shares To Fall After Earnings Report, As Stock Is Up 5% In 2022 - AstraZeneca (NASDAQ:AZN)

AstraZeneca PLC (LSE:AZN) looks set to launch the world's first rescue medication for asthma sufferers that also reduces the underlying inflammation associated with ‘exacerbations' of the condition. A specialist panel of the US Food & Drug Administration voted 16 to one that PT027 had a beneficial impact on adults.

AstraZeneca receives backing for new rescue inhaler

WeWork

The three major U.S. equity indexes closed higher again Monday. The Dow Jones industrials ended the day up 0.13%, the S&P 500 closed 0.09% higher and the Nasdaq saw a gain of 0.25%.

Earnings Previews: AstraZeneca, Nio, WeWork

AstraZeneca's revenue was $10,771 million in the 2nd quarter of 2022, showing a 31% increase from the previous year. Over the past three quarters, a slew of AstraZeneca's medicines have received regulatory approvals from the US, Europe, Japan, and China, thereby maintaining upward pressure on the company's share price.

Most Promising Pharmaceutical Company During A Recession

AstraZeneca PLC (LSE:AZN) and Sanofi's Beyfortus (nirsevimab) immunisation has been approved in the EU for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in infants during their first RSV season.  Beyfortus is the first and only single-dose RSV passive immunisation for the broad infant population, including those born healthy or with specific health conditions, AstraZeneca said in a statement.

AstraZeneca's Beyfortus gets EU approval for RSV in infants

Pharmaceutical giant AstraZeneca has blamed “user error” for leaving a list of credentials online for more than a year that exposed access to sensitive patient data. Mossab Hussein, chief security officer at cybersecurity startup SpiderSilk, told TechCrunch that a developer left the credentials for an AstraZeneca internal server on code sharing site GitHub in 2021.

AstraZeneca password lapse exposed patient data

AstraZeneca can get a boost from the probability that it will close out its US kidney damage lawsuit in New Jersey prior to the first bellwether case in March 2023, according to Citi. The UK pharma is one of several firms embroiled in US legal action over possible damage caused by proton pump inhibitor (PPI) heartburn drugs such as Nexium, launched by Astra in the US in 2001.

AstraZeneca shares will get lift from heartburn litigation closure, says Citi

AstraZeneca plans to grow beyond 2025 by building its innovation pipeline. Investors in the target benefit when a big pharma company acquires an emerging company.

AstraZeneca: Acquisitions And Some Thoughts About Biotech Investing

Mastercard

Verizon

Bargains abound for seniors who want steady long-term appreciation potential.

3 Perfect Stocks Retirees Can Buy Hand Over Fist Right Now

Invitae

– Using Invitae's Ciitizen patient-driven data platform, AstraZeneca and the Cholangiocarcinoma Foundation will access lived experience of patients with a rare cancer to drive further research – – Real-world insights will be translated into cholangiocarcinoma treatment patterns and outcomes in a rapidly evolving disease landscape – SAN FRANCISCO , Oct. 27, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with AstraZeneca (LSE/STO/Nasdaq: AZN) to use Invitae's Ciitizen natural history data in a retrospective and prospective study of patients diagnosed with cholangiocarcinoma, a rare bile duct cancer. This partnership will enable sharing of high-quality, patient-consented data from the patient community of the Cholangiocarcinoma Foundation (CCF), a leading patient advocacy group whose mission is to find a cure and improve the quality of life for those with cholangiocarcinoma.

Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research

Results reinforce commitment to next-generation oral SERD development program

Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer

Capivasertib, a potential first-in-class AKT inhibitor, combined with FASLODEX could become a new option for patients in this setting regardless of biomarker status

Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer

AstraZeneca Plc said on Wednesday its experimental drug capivasertib was able to help patients with an advanced form of breast cancer live longer, when combined with the drugmaker's older cancer treatment Faslodex regardless of biomarker status.

AstraZeneca experimental drug meets main goals of breast cancer study

AstraZeneca PLC said Wednesday that Capivasertib plus Faslodex significantly improved progression-free survival when compared with Faslodex combined with a placebo in a Phase 3 trial in advanced hormone receptor-positive breast cancer.

AstraZeneca says advanced trial of breast-cancer drug Capivasertib meets primary endpoints

Amgen

IQVIA Hlds

Johnson & Johnson

Novartis

Regeneron Pharmaceuticals

Biosimilars are bringing down prescription drug costs without sacrificing quality.

News for AstraZeneca Stock (AZN)